1. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology. 2013; 81:534–540. PMID:
23843466.
Article
2. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The ‘swallow tail’ appearance of the healthy nigrosome-a new accurate test of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014; 9:e93814. PMID:
24710392.
3. Cosottini M, Frosini D, Pesaresi I, Costagli M, Biagi L, Ceravolo R, et al. MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology. 2014; 271:831–838. PMID:
24601752.
Article
4. Cosottini M, Frosini D, Pesaresi I, Donatelli G, Cecchi P, Costagli M, et al. Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol. 2015; 36:461–466. PMID:
25376811.
Article
5. Noh Y, Sung YH, Lee J, Kim EY. Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. AJNR Am J Neuroradiol. 2015; 36:2010–2016. PMID:
26294646.
Article
6. Sung YH, Noh Y, Lee J, Kim EY. Drug-induced Parkinsonism versus idiopathic Parkinson disease: utility of nigrosome 1 with 3-T imaging. Radiology. 2016; 279:849–858. PMID:
26690908.
Article
7. Deh K, Nguyen TD, Eskreis-Winkler S, Prince MR, Spincemaille P, Gauthier S, et al. Reproducibility of quantitative susceptibility mapping in the brain at two field strengths from two vendors. J Magn Reson Imaging. 2015; 42:1592–1600. PMID:
25960320.
Article
8. Lin PY, Chao TC, Wu ML. Quantitative susceptibility mapping of human brain at 3T: a multisite reproducibility study. AJNR Am J Neuroradiol. 2015; 36:467–474. PMID:
25339652.
Article
9. Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, et al. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2
*. Magn Reson Imaging. 2015; 33:559–565. PMID:
25721997.
10. He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, et al. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum Brain Mapp. 2015; 36:4407–4420. PMID:
26249218.
Article
11. Murakami Y, Kakeda S, Watanabe K, Ueda I, Ogasawara A, Moriya J, et al. Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. AJNR Am J Neuroradiol. 2015; 36:1102–1108. PMID:
25767187.
Article
12. Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ, Butryn M, Valdes-Herrera JP, Galazky I, et al. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease. Brain. 2017; 140:118–131. PMID:
27836833.
Article
13. Azuma M, Hirai T, Yamada K, Yamashita S, Ando Y, Tateishi M, et al. Lateral asymmetry and spatial difference of iron deposition in the substantia nigra of patients with Parkinson disease measured with quantitative susceptibility mapping. AJNR Am J Neuroradiol. 2016; 37:782–788. PMID:
26822728.
Article
14. Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, et al. Quantitative susceptibility mapping of the midbrain in Parkinson's disease. Mov Disord. 2016; 31:317–324. PMID:
26362242.
Article
15. Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, et al. Quantitative susceptibility mapping in Parkinson's disease. PLoS One. 2016; 11:e0162460. PMID:
27598250.
Article
16. Guan X, Xuan M, Gu Q, Huang P, Liu C, Wang N, et al. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping. NMR Biomed. 2017; 30:e3489.
Article
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55:181–184. PMID:
1564476.
Article
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967; 17:427–442. PMID:
6067254.
Article
19. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999; 122:1421–1436. PMID:
10430829.
20. Massey LA, Miranda MA, Al-Helli O, Parkes HG, Thornton JS, So PW, et al. 9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease. Neuroimage Clin. 2016; 13:154–163. PMID:
27981030.
Article
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837–845. PMID:
3203132.
Article
22. Wang N, Yang H, Li C, Fan G, Luo X. Using 'swallow-tail' sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: a susceptibility-weighted imaging study. Eur Radiol. 2017; 27:3174–3180. PMID:
28105503.
Article
23. Nam Y, Gho SM, Kim DH, Kim EY, Lee J. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI). J Magn Reson Imaging. 2017; 46:528–536. PMID:
27859983.
Article
24. Bae YJ, Kim JM, Kim E, Lee KM, Kang SY, Park HS, et al. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: comparison with (123) I-FP-CIT SPECT. Mov Disord. 2016; 31:684–692. PMID:
26990970.
25. Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord. 2015; 30:1068–1076. PMID:
25773707.
Article
26. Frosini D, Ceravolo R, Tosetti M, Bonuccelli U, Cosottini M. Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. J Neural Transm (Vienna). 2016; 123:509–513. PMID:
26943945.
Article
27. Oustwani CS, Korutz AW, Lester MS, Kianirad Y, Simuni T, Hijaz TA. Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes? Clin Imaging. 2017; 44:66–69. PMID:
28460362.
Article